Features Screener Stocks Charts
Sign In Sign Up

Caplin Point Laboratories Cash Flow Statement

NSE:CAPLIPOINT | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.64x

CAPLIPOINT's operating cash flow covered 64% of net income in FY 2025. Some earnings may be tied up in working capital.

Free Cash Flow

₹2.41B

CAPLIPOINT's free cash flow was ₹2.41B in FY 2025, up 39.6% from FY 2024.

Dividend Coverage

6.3x

CAPLIPOINT's free cash flow covered dividends 6.3x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

44.3%

Capital expenditure was 44.3% of operating cash flow in FY 2025 for CAPLIPOINT, a moderate level of reinvestment.

2-year CAPLIPOINT cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 5.64B 6.77B
Cash flow Operating Activities 3.18B 4.32B
Investments in PPE -1.46B -1.92B
Cash flow Investing Activities -3.20B -3.35B
Dividend Paid -341.70M -379.90M
Cash flow Financing Activities -380.70M -383.20M
Cash at beginning of period 1.78B 1.39B
Cash at end of period 1.39B 1.94B
Free Cash Flow 1.73B 2.41B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025